S-benzylglutathione
Also known as: Glo1 inhibitor reference compound, S-Benzyl-GSH, S-Benzylglutathione tripeptide, γ-L-Glutamyl-S-benzyl-L-cysteinylglycine
Summary
S-Benzylglutathione is a synthetic tripeptide (γ-Glu-Cys(S-Bn)-Gly) derived from glutathione by S-benzylation of the cysteine thiol. It is a well-characterized biochemical tool compound used to study the glyoxalase system and glutathione S-transferases. It has shown antiproliferative activity in cancer cell lines and is explored as a lead structure for antitumor and antiparasitic agents, but has no approved clinical use.
Mechanism of Action
Competitive inhibitor of glyoxalase I (Glo1); binds the active site of Glo1 by mimicking the hemithioacetal substrate, blocking conversion of methylglyoxal to S-lactoylglutathione and thereby disrupting detoxification of reactive carbonyl species. Also inhibits certain glutathione S-transferases.
Routes of Administration
Goals & Uses
- Antiparasitic leadInfectious Disease ResearchLow
- Anticancer activityOncologyLow
- GST characterizationBiochemical ToolModerate
- Glyoxalase I inhibitionEnzyme Inhibition / Biochemical ToolHigh
Contraindications
- Human therapeutic administrationClinical UseHigh
Adverse Effects
- CytotoxicityCell ViabilityUnknown
Drug Interactions
- Methylglyoxal-metabolizing agentsLow
Population Constraints
- General human populationRegulatory/safetyAbsolute
Regulatory Status
- European UnionUnapprovedResearch reagent; no marketing authorization.
- United StatesUnapprovedResearch chemical only; not an IND or approved drug.
- United KingdomUnapprovedResearch use only; no MHRA authorization.
Not approved by any regulatory authority for human therapeutic use. Used exclusively as a research/laboratory reagent and pharmacological tool.
Evidence & Sources
No sources recorded yet.